AR and neoplasm: While our data do not allow to draw causal conclusions in terms of the interplay between CAFs and AR expression in tumor cells, SDC patients with ARhigh tumors could particularly benefit from CAF-targeted therapies or therapies combining androgen blockade and CAF-targeting.